Published online before print March 3, 2003, doi: 10.1161/01.HYP.0000061116.20490.8D
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2003;41:978.)
© 2003 American Heart Association, Inc.
Scientific Contributions |
Plasma Brain Natriuretic Peptide Levels and Blood Pressure Tracking in the Framingham Heart Study
From the National Heart, Lung, and Blood Institute’s Framingham Heart Study (M.H.F., M.G.L., D.L., E.J.B., T.J.W., E.P.L., P.W.F.W., R.S.V.), Framingham, Mass; The MetroWest Medical Center (M.H.F.), Framingham, Mass; the Divisions of Cardiology and Clinical Epidemiology, Beth Israel Deaconess Medical Center, Harvard Medical School (D.L.), Boston, Mass; the National Heart, Lung, and Blood Institute (D.L.), Bethesda, Md; and the Cardiology Section (E.J.B., R.S.V.), Endocrinology Section (P.W.F.W.), and Department of Preventive Medicine and Epidemiology (M.G.L., D.L., E.J.B., P.W.F.W., R.S.V.), Boston University School of Medicine, Boston, Mass.
Correspondence to Ramachandran S. Vasan, MD, Framingham Heart Study, 73 Mount Wayte Ave, Suite 2, Framingham, MA 01702-5827. E-mail vasan{at}fram.nhlbi.nih.gov
Increased brain natriuretic peptide (BNP) expression in the ventricles antedates elevated blood pressure (BP) in experimental studies. We hypothesized that higher plasma BNP levels in nonhypertensive individuals may be associated with a greater likelihood of future BP increase and/or hypertension. We evaluated the relations of plasma BNP to longitudinal BP tracking and incidence of hypertension in 1801 nonhypertensive Framingham Heart Study participants (mean age, 56 years; 57% women) by using gender-specific multivariable logistic regression. Progression of BP stage was defined as an increment of one or more BP categories, as classified by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Hypertension was defined as a systolic BP 
140 or diastolic BP 90 mm Hg or use of antihypertensive medications. On follow-up 4 years from baseline, progression of BP category was observed in 36.2% of men and 33.1% of women; hypertension developed in 16.4% of men and 15.5% of women. In multivariable models adjusting for known risk factors, elevated plasma BNP level was associated with increased risk of BP progression in men (odds ratio of 1.15 for trend across categories, P=0.046) but not in women (P=0.82). There were no significant trends of increasing incidence of hypertension across BNP categories in men or women. In our community-based sample, higher plasma BNP levels were associated with increased risk of BP progression in men but not women. Additional investigations are warranted to confirm these findings and elucidate the basis for these gender-related differences.
Key Words: natriuretic peptides • blood pressure • hypertension, essential • epidemiology • hemodynamics
This article has been cited by other articles:
 |
|
 |
|
  A. Cataliotti, H. H. Chen, J. A. Schirger, F. L. Martin, G. Boerrigter, L. C. Costello-Boerrigter, K. D. James, K. Polowy, M. A. Miller, N. B. Malkar, et al. Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II-Mediated Hypertension Circulation, October 21, 2008; 118(17): 1729 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ingelsson, M. J. Pencina, G. H. Tofler, E. J. Benjamin, K. J. Lanier, P. F. Jacques, C. S. Fox, J. B. Meigs, D. Levy, M. G. Larson, et al. Multimarker Approach to Evaluate the Incidence of the Metabolic Syndrome and Longitudinal Changes in Metabolic Risk Factors: The Framingham Offspring Study Circulation, August 28, 2007; 116(9): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Levy, S.-J. Hwang, A. Kayalar, E. J. Benjamin, R. S. Vasan, H. Parise, M. G. Larson, T. J. Wang, J. Selhub, P. F. Jacques, et al. Associations of Plasma Natriuretic Peptide, Adrenomedullin, and Homocysteine Levels With Alterations in Arterial Stiffness: The Framingham Heart Study Circulation, June 19, 2007; 115(24): 3079 - 3085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Wang, P. Gona, M. G. Larson, D. Levy, E. J. Benjamin, G. H. Tofler, P. F. Jacques, J. B. Meigs, N. Rifai, J. Selhub, et al. Multiple Biomarkers and the Risk of Incident Hypertension Hypertension, March 1, 2007; 49(3): 432 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Belluardo, A. Cataliotti, L. Bonaiuto, E. Giuffre, E. Maugeri, P. Noto, G. Orlando, G. Raspa, B. Piazza, L. Babuin, et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy Am J Physiol Heart Circ Physiol, October 1, 2006; 291(4): H1529 - H1535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Wang, J. C. Evans, J. B. Meigs, N. Rifai, C. S. Fox, R. B. D'Agostino, D. Levy, and R. S. Vasan Low-Grade Albuminuria and the Risks of Hypertension and Blood Pressure Progression Circulation, March 22, 2005; 111(11): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Goetze Biochemistry of Pro-B-Type Natriuretic Peptide-Derived Peptides: The Endocrine Heart Revisited Clin. Chem., September 1, 2004; 50(9): 1503 - 1510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hocher, R. Ziebig, R. Krause, G. Asmus, H.-H Neumayer, L. Liefeldt, and J.-P. Stasch Relaxin Is an Independent Risk Factor Predicting Death in Male Patients With End-Stage Kidney Disease Circulation, May 18, 2004; 109(19): 2266 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Hildebrandt, M. Boesen, M. Olsen, K. Wachtell, and B. Groenning N-terminal pro brain natriuretic peptide in arterial hypertension--a marker for left ventricular dimensions and prognosis Eur J Heart Fail, March 15, 2004; 6(3): 313 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Clerico and M. Emdin Diagnostic Accuracy and Prognostic Relevance of the Measurement of Cardiac Natriuretic Peptides: A Review Clin. Chem., January 1, 2004; 50(1): 33 - 50. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, April 26, 2003; 326(7395): 940 - 940. [Full Text] [PDF]
|
|